Related Experiment Video
Updated: Mar 7, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
26.5K
New-Generation Coronary Stents: Current Data and Future Directions
Ankur Kalra1,2,3, Hasan Rehman1, Sahil Khera4
1Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, USA.
Current Atherosclerosis Reports
|February 22, 2017
Summary
Second-generation drug-eluting stents, particularly everolimus-eluting stents, offer superior outcomes for coronary artery disease treatment. Newer innovations like bioabsorbable scaffolds show concerning thrombosis risks and lack data to replace current standards.
Area of Science:
- Interventional Cardiology
- Biomaterials Science
- Cardiovascular Research
Background:
- Drug-eluting stents (DES) are primary treatment for coronary artery disease via percutaneous coronary intervention.
- Innovations aim to improve upon first-generation stents, including biodegradable polymer stents, polymer-free DES, and bioabsorbable scaffolds.
Purpose of the Study:
- To review clinical profiles of first- and second-generation coronary stents.
- To provide an overview of newer coronary stent designs, technologies, safety, and efficacy.
- To discuss relevant clinical trials in interventional cardiology.
Main Methods:
- Review of clinical profiles of coronary stents.
- Analysis of design, technology, safety, and efficacy data.
- Discussion of clinical trial outcomes for various stent generations and types.
Main Results:
- Second-generation everolimus-eluting stents (EES) show superior outcomes to first-generation stents (paclitaxel- and sirolimus-eluting).
- Second-generation zotarolimus-eluting stents show similar outcomes to EES, with less evidence.
- Biodegradable polymer stents and bioabsorbable scaffolds have not demonstrated superiority and, in the case of scaffolds, show a concerning risk of late stent thrombosis.
Conclusions:
- Everolimus-eluting stents offer the most favorable safety and efficacy profile for percutaneous coronary intervention.
- Biodegradable polymers and bioabsorbable scaffolds require more clinical data before replacing current second-generation DES standards.
- Second-generation DES remain the current standard of care for coronary artery disease treatment.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
357
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
01:30Acute Coronary Syndrome III: Diagnostic Studies
355
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
355
01:26Coronary Artery Disease IV: Preventive Measures
789
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
789
01:28Acute Coronary Syndrome IV: Interprofessional Care
360
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
360
01:30Coronary Artery Disease I: Introduction
1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
01:26Atherosclerosis III: Management
540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540